Opendata, web and dolomites


New vaccine for a paradigm shift in Brucellosis, one of the world’s most widespread zoonotic diseases affecting humans

Total Cost €


EC-Contrib. €






 BGV1 project word cloud

Explore the words cloud of the BGV1 project. It provides you a very rough idea of what is the project "BGV1" about.

brucella    exhibiting    virulence    regions    unnecessary    economic    lives    incidence    cumulative    mass    paradigm    greenvac    bioterrorism    africa    safety    small    humans    antibiotics    enhanced    anyone    zoonotic    melitensis    successful    keepers    america    outbreaks    animal    diagnostic    pregnant    virulent    lower    overcomes    serious    minimal    candidate    mediterranean    mainly    lactating    81bn    benefits    suffer    resistance    caused    ruminants    world    first    evading    severely    interference    disease    profile    eliminate    combined    species    brucellosis    shift    globalisation    replace    asia    serodiagnostic    science    anywhere    impacts    protective    rising    amidst    antibiotic    standard    drawbacks    relatively    transmissibility    2028    designed    vaccine    environmental    endemic    vaccines    medicine    safe    time    infection    vaccination    classic    treatable    rate    livelihoods    global    generate    livestock    animals    integration    health    veterinary    latin    losses    1950s    diagnostics    avirulent    radical    limited    threats    poor    residual    prevalent    bgv1    efficacy    eradication    human    tests   

Project "BGV1" data sheet

The following table provides information about the project.


Organization address
address: PLAZA LAMITURRI, 10, 1 A
postcode: 31192
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 2˙005˙250 €
 EC max contribution 1˙403˙675 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-SMEInst-2018-2020-3
 Funding Scheme SME-2b
 Starting year 2020
 Duration (year-month-day) from 2020-03-01   to  2022-02-28


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BRUCELLA GREEN VAC SL ES (MUTILVA) coordinator 1˙403˙675.00


 Project objective

Brucellosis is the world’s most widespread zoonotic disease. It is a global problem but most severely affects poor livestock keepers in the developing world because of its impacts on human and animal health and livelihoods. Brucellosis is endemic in most of Asia, Africa and Latin America and is prevalent in the EU Mediterranean regions. Currently vaccines for Brucellosis, around since the 1950s, suffer from serious safety drawbacks mainly due to residual virulence for animals and humans. Combined with rising antibiotic resistance, their use is relatively limited.

GreenVac is developing BGV1, the first vaccine in over 60 years against Brucella melitensis in small ruminants that overcomes the main drawbacks of existing vaccines. BGV1 has been designed to a) be avirulent for animals, b) eliminate interference with diagnostic tests after vaccination, c) have low potential transmissibility to humans and, d) be treatable with standard antibiotics. BGV1 is a strong candidate to replace the classic virulent vaccine, exhibiting a safe profile with an enhanced protective efficacy, no residual virulence and minimal serodiagnostic interference.

A successful BGV1 EU-project will allow, for the first time, mass vaccination of any animal at any time (including pregnant and lactating animals), which is a radical paradigm shift in Brucellosis control and eradication. The reduction of B. melitensis outbreaks and infection rate in animals will generate €3.81bn in cumulative economic benefits for users by 2028 by evading unnecessary diagnostics costs and losses caused by the infection. It will lead to a lower disease incidence in humans amidst ever rising globalisation and bioterrorism threats to anyone, anywhere. BGV1 will contribute to the objectives of the One Health Initiative: One World, One Health, One Medicine to improve the lives of all species through the integration of human medicine, veterinary medicine and environmental science.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BGV1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BGV1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

C-Air (2018)

An innovative, reliable, lifesaving industrial air purification system that contains, cleans, and purifies air contaminated by toxic gases.

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More